ABBVIE INC. (ABBV)
AbbVie Inc. (ABBV) is a global biopharmaceutical company founded in 2013 as a spin-off from Abbott Laboratories. It specializes in the research, development, and marketing of innovative medicines across a range of therapeutic areas, including immunology, oncology, virology, and neuroscience. AbbVie is known for its flagship product, Humira, a leading treatment for autoimmune diseases. The company focuses on advancing scientific discoveries to deliver novel therapies and improve patient outcomes worldwide.
Dividend History
Investors can expect a dividend payout of $1.73 per share, scheduled to be distributed in 88 days on February 17, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 17, 2026 | $1.73 | 2026-01-16 | 2026-01-16 |
| November 14, 2025 | $1.64 | 2025-10-15 | 2025-10-15 |
| August 15, 2025 | $1.64 | 2025-07-15 | 2025-07-15 |
| May 15, 2025 | $1.64 | 2025-04-15 | 2025-04-15 |
| February 14, 2025 | $1.64 | 2025-01-15 | 2025-01-15 |
Dividends Summary
- ABBVIE INC. has issued 53 dividend payments over the past 13 years
- The most recent dividend was paid 7 days ago, on November 14, 2025
- The highest dividend payed out to investors during this period was $1.73 per share
- The average dividend paid during this period was $1.02 per share.
Company News
Johnson & Johnson reported strong Q3 results, beat Wall Street estimates, and announced the acquisition of Halda Therapeutics for $3.05 billion, focusing on expanding its oncology drug pipeline and offsetting competition in existing drug markets.
Healthcare stocks are experiencing a sector rotation as investors move away from tech, with three large-cap pharmaceutical companies showing strong potential due to attractive valuations, breakthrough drugs, and promising earnings.
ADARx Pharmaceuticals reported successful Phase 1 clinical trial results for ADX-038, an investigational siRNA therapy targeting complement factor B. A single subcutaneous dose demonstrated near-complete alternative pathway suppression for 6 months, with potential applications in renal, hematologic, and ocular diseases.
AbbVie reported strong Q3 2025 financial results with $15.78 billion in sales, increased dividend to $1.73 per share, and raised fiscal 2025 earnings guidance to $10.61-$10.65 per share, driven by robust immunology portfolio growth.
The article discusses the Invesco Large Cap Value ETF (PWV), which provides broad exposure to the large-cap value segment of the market. It highlights the fund's investment strategy, performance, and risk profile, as well as compares it to similar ETFs like Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Value ETF (VTV).
